Imbruvica (ibrutinib) — United Healthcare

Initial criteria

• Diagnosis of chronic graft versus host disease AND history of failure of at least one other systemic therapy (e.g., corticosteroids, mycophenolate, etc.)

Reauthorization criteria

• Patient shows evidence of positive clinical response while on Imbruvica therapy

Approval duration

12 months